FDA opens FY2027 MUMS grant applications for animal drug studies: full analysis

The FDA’s Center for Veterinary Medicine has opened the first fiscal 2027 application period for grants supporting animal drugs for minor uses and minor species, or MUMS, a program aimed at products that often face thin commercial incentives despite clear clinical need. In its May 22 announcement, FDA said the funding is intended to support development work that can lead to approval or conditional approval of new animal drugs for uncommon diseases in major species or for minor species. (fda.gov)

The move builds on a long-running federal effort to make limited-market animal drug development more feasible. FDA says the MUMS Act of 2004 created incentives for sponsors pursuing these products, including grants and marketing exclusivity, because companies had historically been less likely to invest in therapies for small populations or uncommon conditions. In December 2023, FDA also issued final Guidance for Industry #61 to help sponsors navigate the MUMS approval pathway, underscoring that the agency is still trying to reduce development friction in this space. (fda.gov)

For this funding round, individual awards can total as much as $250,000 per year. FDA said routine safety, effectiveness, and some manufacturing studies may be funded for up to two years, for a maximum of $500,000 total, while toxicology studies may be funded for up to three years, for a maximum of $750,000 total, subject to available appropriations. Eligibility is limited to sponsors with designated MUMS drugs or their research partners, and applications must be submitted through NIH ASSIST or Grants.gov. The optional letter of intent is due June 19, 2026, and the application deadline is July 24, 2026. (fda.gov)

FDA’s own background materials add useful context for applicants. The agency says the MUMS grant program has supported 72 studies with $8.4 million to date, including work tied to parasitic and bacterial diseases in fish, certain cancers in dogs, and uses in horses, pheasants, and goats. FDA’s grant overview also notes that the program operates with two open application periods per fiscal year, with a second FY 2027 window scheduled for November 27, 2026, through January 29, 2027. (fda.gov)

Direct outside reaction to this specific announcement appears limited so far, but the broader industry message has been consistent: MUMS incentives matter because the economics of adding species or niche indications are difficult. A recent FDA update presented to the sheep industry cited discussion from an AVMA MUMS roundtable that drug companies may spend roughly $10 million to $25 million to add a species to a label, a reminder of why even relatively modest federal grants can be meaningful in early development planning. That figure comes from an industry-facing presentation rather than a formal economic analysis, so it should be read as directional, but it aligns with FDA’s longstanding rationale for the program. (sheepusa.org)

The announcement also lands as CVM is using grants more strategically across its portfolio. Earlier this month, FDA opened a separate FY 2026 funding opportunity for Animal and Veterinary Innovation Centers, or AVICs, described as long-term research partnerships with public and private academic institutions. CVM said it is seeking work in four priority areas: aquaculture, minor ruminant species, human food safety for minor species drugs, and antimicrobial use and stewardship. The agency said it may initiate up to five AVIC grants in FY 2026, with funding potentially renewable for up to four years depending on progress and available funds. CVM also scheduled a virtual public technical session for May 11, 2026, to walk interested applicants through that opportunity. (fda.gov; dvm360.com)

That broader grant activity matters because the same problem shows up across multiple corners of veterinary medicine: limited commercial incentives can leave clinicians with too few approved options. In aquaculture and minor ruminants, for example, sparse labeled drug availability has long pushed practitioners toward extra-label use and the regulatory and safety complications that come with it. And on antimicrobial stewardship, research funded through AVICs could influence future expectations around judicious use of medically important drugs in food-producing animals. Read together, the MUMS and AVIC programs suggest CVM is trying to support both product-specific development and the wider regulatory science base behind veterinary drug availability. That is an inference from the agency’s recent funding priorities, but it fits the pattern of the announcements. (dvm360.com; fda.gov)

Why it matters: For veterinarians, especially those working in food animal medicine, equine practice, exotics, aquaculture, oncology, and other underserved segments, the MUMS program is less about a single grant cycle and more about whether the pipeline for approved therapies keeps moving. When limited-market products stall, clinicians are left with fewer labeled options, more reliance on workarounds, and tougher conversations with pet parents and producers about access, evidence, withdrawal considerations, or stewardship. Grants at this stage won’t solve every access problem, but they can help generate the safety, effectiveness, manufacturing, and toxicology data sponsors need to keep a product on a regulatory path. The parallel AVIC effort reinforces the same point from another angle: FDA is also investing in research areas where practitioners most often feel the consequences of thin drug pipelines, including aquaculture, minor ruminants, food safety, and antimicrobial decision-making. (fda.gov; fda.gov; dvm360.com)

What to watch: The immediate milestone is the July 24, 2026, application deadline, followed by whether FDA highlights funded projects later in the cycle. Beyond that, the second FY 2027 MUMS application window, set for late November 2026 through late January 2027, will show whether the agency has remaining funds to deploy and where sponsor interest is strongest. The separate AVIC competition is also worth watching as a signal of where CVM sees the biggest unmet research needs, particularly in aquaculture, minor ruminants, human food safety for minor species drugs, and antimicrobial stewardship. (fda.gov; fda.gov)